Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

The goal of this clinical trial is to learn if donafenib combined with or without immunotherapy and local therapy works to treat unresectable hepatocellular carcinoma that has failed in previous therapy. It will also learn about the safety of donafenib combined with immunotherapy and local therapy. The main questions it aims to answer are: The Objective Response Rate (mRecist） and Progression-Free Survival of the participants treated by donafenib combined with immunotherapy and local therapy. The disease control rate and overall survival of the participants treated by donafenib combined with immunotherapy and local therapy. The safety of donafenib combined with immunotherapy and local therapy in the participants. Participants will: Replace the original targeted drug with donafenib (0.2g bid), while continuing immunotherapy and local therapy as previous therapy (if have). The observation period was 1 year.

NCT Number	NCT06496815
Lead Sponsor	Tongji Hospital
Conditions	Unresectable Hepatocellular Carcinoma
Enrollment	32 participants
Start Date	2024-08-01
Primary Completion	2026-08-01 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2024-07-11